Loading…

Recurrence of Ewing sarcoma: Is detection by imaging follow‐up protocol associated with survival advantage?

Background The Cooperative Ewing Sarcoma Study and the Late Effects Surveillance System of the Society for Paediatric Oncology and Haematology recommend a structured follow‐up imaging protocol (FUIP) for patients with Ewing sarcoma (EwS) with decreasing frequency of imaging over the first 5 years. T...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2018-07, Vol.65 (7), p.e27011-n/a
Main Authors: Heinemann, Melina, Ranft, Andreas, Langer, Thorsten, Jürgens, Herbert, Kreyer, Justus, Vieth, Volker, Schäfers, Michael, Weckesser, Matthias, Simon, Thorsten, Hassenpflug, Wolf, Corbacioglu, Selim, Bielack, Stefan, Mayer‐Steinacker, Regina, Kühne, Thomas, den Berg, Henk, Gelderblom, Hans, Bauer, Sebastian, Stegger, Lars, Dirksen, Uta
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The Cooperative Ewing Sarcoma Study and the Late Effects Surveillance System of the Society for Paediatric Oncology and Haematology recommend a structured follow‐up imaging protocol (FUIP) for patients with Ewing sarcoma (EwS) with decreasing frequency of imaging over the first 5 years. The present study aims to assess the effectiveness of the FUIP for EwS patients regarding survival after relapse. Patients and methods A retrospective multicenter analysis on 160 eligible patients with EwS recurrence was performed. Potential survival differences following recurrence diagnosis between patients with protocol‐detected and symptomatic relapse were investigated using the Kaplan–Meier method. Additional subgroup analyses were performed on the relapse type. Overall survival (OS) was calculated from diagnosis of relapse to last follow‐up or death. Results In the multicenter analysis, recurrence was detected by FUIP in 77 of 160 patients (48%) and due to symptoms in 83 patients (52%). Regarding the entire study population, OS was significantly superior in patients with protocol‐detected relapse compared to patients with symptomatic relapse (median, 2.4 vs. 1.2 years; P 
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.27011